Teva Pharmaceutical Industries Ltd. has entered into a patent settlement agreement with Pfizer Inc. on Teva's planned generic version of Celebrex.


Teva Pharmaceutical Industries, Celebrex, Teva Pharmaceuticals USA, generic version of Celebrex, Celebrex generic, Pfizer, patent settlement, celecoxib














































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Teva settles with Pfizer on generic Celebrex

April 18th, 2014

JERUSALEM – Teva Pharmaceutical Industries Ltd. has entered into a patent settlement agreement with Pfizer Inc. on Teva's planned generic version of Celebrex.

Teva said Thursday that under the terms of the settlement, made with its Teva Pharmaceuticals USA Inc. subsidiary, the comapny can launch its Celebrex generic versions in December, or earlier under certain circumstances, in the United States.

The settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) in 50-, 100-, 200- and 400-mg capsules.

Teva said it has gained tentative approval from the Food and Drug Administration for all strengths of celecoxib and believes that it is first-to-file on at least the 100-, 200- and 400-mg capsules.

A nonsteroidal anti-inflammatory drug (NSAID), Celebrex is indicated for the treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain and primary dysmenorrhea.

U.S. sales of Celebrex totaled $2.2 billion through December 2013, according to IMS Health figures reported by Teva.

Advertisement